汉字是象形文字,其字形特征对于中文命名实体识别有着重要的作用。针对双向长短期记忆模型(bi-directional long short-term memory,BiLSTM)提取部首,命名实体识别准确率不高的问题,提出笔画组成编码器,用于获取汉字的字形特征,并将笔...汉字是象形文字,其字形特征对于中文命名实体识别有着重要的作用。针对双向长短期记忆模型(bi-directional long short-term memory,BiLSTM)提取部首,命名实体识别准确率不高的问题,提出笔画组成编码器,用于获取汉字的字形特征,并将笔画字形特征向量和预训练的语言表征模型(bidirectional encoder representation from transformers,BERT)输出的字向量进行拼接,将拼接后的向量放入双向长短期记忆模型与条件随机场(conditional random field,CRF)相连的标注模型(BiLSTM-CRF)中进行命名实体识别。实验表明,所提的方法在Resume数据集上命名实体识别准确率有显著提升。相较于用卷积神经网络做编码器提取汉字字形特征,准确率高出0.4%。相较于使用BiLSTM提取的部首特征模型和加入词典的长短期记忆模型(lattice LSTM),其准确率分别提升了4.2%、0.8%。展开更多
Background △DNMT3B （a new DNMT3B subfamily） expression is initiated through a novel promoter. We identified at least 7 transcription variants of △DNMT3B as a result of alternative pre-mRNA processing. The aim of t...Background △DNMT3B （a new DNMT3B subfamily） expression is initiated through a novel promoter. We identified at least 7 transcription variants of △DNMT3B as a result of alternative pre-mRNA processing. The aim of this study was to detect the expression pattern of ,△DNMT3B variants in non-small cell lung cancer （NSCLC） and to explore the role of △DNMT3B variants in regulating the promoter-specific DNA methylation. Methods Specific polymerase chain reaction （PCR） primer sets were designed to distinguish individual △DNMT3B variants according to their splicing patterns. The expressions of seven △DNMT3B variants were measured in 13 cell lines, 109 NSCLC patients, and the corresponding normal lung tissues using reverse transcription-PCR （RT-PCR）. The status of the p16 and RASSFIA promoter methylations in the tumors was detected using a methylation specific PCR （MSP）. The relationships of the expression patterns of the △DNMT3B variants were analyzed by observing the status of p16 and RASSFIA promoter methylations in the tumors. The siRNA and the anti-sense oligo-dioxynucleotide specifically targeting the junction of exon 5 and 7 of △DNMT3B were designed and transfected by lipofectmane 2000 into H1299 and H358 cell lines. RASSFIA promoter methylation from cells treated by siRNA-△DNMT3B4/2 was detected using MSP and Bisulfite sequencing, and Western blotting was used to △DNMT3B. Cell growth and cell cycle distribution were measured flowcytometry, respectively. detect the protein expression of DNMT3B and by applying real-time cell growth analysis and Results △DNMT3B variants, not DNMT3B, were the predominant transcripts in both NSCLC cell lines and primary tumors. The expression of △DNMT3B4 strongly correlated to the promoter methylation status of RASSFIA in a primary NSCLC. The knockdown of △DNMT3B4/2 by RNA-interference or anti-sense approaches resulted in a complete demethylation of RASSFIA promoter with the reactivation of a RASSFIA gene expression in less than 12 hours, but no effect resulted from the p16INK4a promoter in the NSCLC cell lines. Conclusions These results demonstrate an important role of ,△DNMT3B4/2 in the maintenance of promoter-specific DNA methylation in a cell type specific manner and provide a novel cell model for the study of the regulation of replication-independent DNA methylation.展开更多
Background The genotype of epidermal growth factor receptor （EGFR） is associated with tyrosine kinase inhibitor and effectiveness of therapy, but its role in cytotoxic chemotherapy is still unknown. Previous studies...Background The genotype of epidermal growth factor receptor （EGFR） is associated with tyrosine kinase inhibitor and effectiveness of therapy, but its role in cytotoxic chemotherapy is still unknown. Previous studies indicated that certain EGFR mutations were associated with response and progression free survival following platinum based chemotherapy. Our recent studies have identified that EGFR genotypes in the tumour tissues were not associated with response to the first-line chemotherapy in Chinese patients with advanced non-small cell lung cancer （NSCLC）. In this study, we investigated associations of EGFR genotypes from plasma of patients with advanced NSCLC and response to first-line chemotherapy and prognosis. Methods We enrolled 145 advanced NSCLC patients who had received first-line chemotherapy in our department. We examined plasma EGFR genotypes for these patients and associations of EGFR mutations with response to chemotherapy and clinical outcomes. Results There were 54 patients with known EGFR mutations and 91 cases of wild types. No significant difference was detected in the response rate to first-line chemotherapy between mutation carriers and wild-type patients （37.0% vs. 31.9%）. The median survival time and 1-, 2-year survival rates were higher in mutation carriers than wild-types （24 months vs. 18 months, 85.7% vs. 65.7% and 43.7% vs. 25.9%, P=0.047）. Clinical stage （Ⅳvs. Ⅲb）, response to the first-line chemotherapy （partial vs. no） and EGFR genotype were independent prognostic factors. Conclusion Plasma EGFR mutations in the Chinese patients with advanced NSCLC is not a predictor for the response to first-line chemotherapy, but an independent prognostic factor indicating longer survival.展开更多
本文概述了数字化远程智能临床试验开展现状,重点介绍了电子源数据(eSource)到电子数据采集系统(EDC)的建设思路、应用情况以及成本效率、数据安全、流程合规等多维度价值。与传统模式相比,eSource to EDC(E2E)模式利用电子源数据平台...本文概述了数字化远程智能临床试验开展现状,重点介绍了电子源数据(eSource)到电子数据采集系统(EDC)的建设思路、应用情况以及成本效率、数据安全、流程合规等多维度价值。与传统模式相比,eSource to EDC(E2E)模式利用电子源数据平台、电子数据采集、远程监查等系统的有效融合,做到更小化人工干预,系统性地提升临床研究效率和数据质量。在保证数据安全与个人信息隐私的前提下,实现数据和操作的有效监管,达到国内外相关法律法规要求,为进一步探索临床研究信息化转型提供参考依据。展开更多
文摘汉字是象形文字,其字形特征对于中文命名实体识别有着重要的作用。针对双向长短期记忆模型(bi-directional long short-term memory,BiLSTM)提取部首,命名实体识别准确率不高的问题,提出笔画组成编码器,用于获取汉字的字形特征,并将笔画字形特征向量和预训练的语言表征模型(bidirectional encoder representation from transformers,BERT)输出的字向量进行拼接,将拼接后的向量放入双向长短期记忆模型与条件随机场(conditional random field,CRF)相连的标注模型(BiLSTM-CRF)中进行命名实体识别。实验表明,所提的方法在Resume数据集上命名实体识别准确率有显著提升。相较于用卷积神经网络做编码器提取汉字字形特征,准确率高出0.4%。相较于使用BiLSTM提取的部首特征模型和加入词典的长短期记忆模型(lattice LSTM),其准确率分别提升了4.2%、0.8%。
基金This study was supported by grants from the National Natural Science Foundation of China （No. 30572104, 30772472）, the Capital Medical Developing Foundation （No. 2005-2022）, and the 985 Project （No. 985-2-013-39）.
文摘Background △DNMT3B （a new DNMT3B subfamily） expression is initiated through a novel promoter. We identified at least 7 transcription variants of △DNMT3B as a result of alternative pre-mRNA processing. The aim of this study was to detect the expression pattern of ,△DNMT3B variants in non-small cell lung cancer （NSCLC） and to explore the role of △DNMT3B variants in regulating the promoter-specific DNA methylation. Methods Specific polymerase chain reaction （PCR） primer sets were designed to distinguish individual △DNMT3B variants according to their splicing patterns. The expressions of seven △DNMT3B variants were measured in 13 cell lines, 109 NSCLC patients, and the corresponding normal lung tissues using reverse transcription-PCR （RT-PCR）. The status of the p16 and RASSFIA promoter methylations in the tumors was detected using a methylation specific PCR （MSP）. The relationships of the expression patterns of the △DNMT3B variants were analyzed by observing the status of p16 and RASSFIA promoter methylations in the tumors. The siRNA and the anti-sense oligo-dioxynucleotide specifically targeting the junction of exon 5 and 7 of △DNMT3B were designed and transfected by lipofectmane 2000 into H1299 and H358 cell lines. RASSFIA promoter methylation from cells treated by siRNA-△DNMT3B4/2 was detected using MSP and Bisulfite sequencing, and Western blotting was used to △DNMT3B. Cell growth and cell cycle distribution were measured flowcytometry, respectively. detect the protein expression of DNMT3B and by applying real-time cell growth analysis and Results △DNMT3B variants, not DNMT3B, were the predominant transcripts in both NSCLC cell lines and primary tumors. The expression of △DNMT3B4 strongly correlated to the promoter methylation status of RASSFIA in a primary NSCLC. The knockdown of △DNMT3B4/2 by RNA-interference or anti-sense approaches resulted in a complete demethylation of RASSFIA promoter with the reactivation of a RASSFIA gene expression in less than 12 hours, but no effect resulted from the p16INK4a promoter in the NSCLC cell lines. Conclusions These results demonstrate an important role of ,△DNMT3B4/2 in the maintenance of promoter-specific DNA methylation in a cell type specific manner and provide a novel cell model for the study of the regulation of replication-independent DNA methylation.
文摘Background The genotype of epidermal growth factor receptor （EGFR） is associated with tyrosine kinase inhibitor and effectiveness of therapy, but its role in cytotoxic chemotherapy is still unknown. Previous studies indicated that certain EGFR mutations were associated with response and progression free survival following platinum based chemotherapy. Our recent studies have identified that EGFR genotypes in the tumour tissues were not associated with response to the first-line chemotherapy in Chinese patients with advanced non-small cell lung cancer （NSCLC）. In this study, we investigated associations of EGFR genotypes from plasma of patients with advanced NSCLC and response to first-line chemotherapy and prognosis. Methods We enrolled 145 advanced NSCLC patients who had received first-line chemotherapy in our department. We examined plasma EGFR genotypes for these patients and associations of EGFR mutations with response to chemotherapy and clinical outcomes. Results There were 54 patients with known EGFR mutations and 91 cases of wild types. No significant difference was detected in the response rate to first-line chemotherapy between mutation carriers and wild-type patients （37.0% vs. 31.9%）. The median survival time and 1-, 2-year survival rates were higher in mutation carriers than wild-types （24 months vs. 18 months, 85.7% vs. 65.7% and 43.7% vs. 25.9%, P=0.047）. Clinical stage （Ⅳvs. Ⅲb）, response to the first-line chemotherapy （partial vs. no） and EGFR genotype were independent prognostic factors. Conclusion Plasma EGFR mutations in the Chinese patients with advanced NSCLC is not a predictor for the response to first-line chemotherapy, but an independent prognostic factor indicating longer survival.
文摘本文概述了数字化远程智能临床试验开展现状,重点介绍了电子源数据(eSource)到电子数据采集系统(EDC)的建设思路、应用情况以及成本效率、数据安全、流程合规等多维度价值。与传统模式相比,eSource to EDC(E2E)模式利用电子源数据平台、电子数据采集、远程监查等系统的有效融合,做到更小化人工干预,系统性地提升临床研究效率和数据质量。在保证数据安全与个人信息隐私的前提下,实现数据和操作的有效监管,达到国内外相关法律法规要求,为进一步探索临床研究信息化转型提供参考依据。
